Core--In vivo verification of discovered/associated polymorphisms

$0U01FY2001HLNIH

University Of California San Diego, La Jolla CA

Investigators

Linked publications & trials

Paper 23786442 Paper 22676942 Paper 22403620 Paper 21562465 Paper 21372283 Paper 21156931 Paper 21127457 Paper 20729505 Paper 19706599 Paper 19671882 Paper 19407804 Paper 19372204 Paper 18946466 Paper 18615004 Paper 18075471 Paper 17991725 Paper 17700361 Paper 17531579 Paper 17267549 Paper 17159089 Paper 16987240 Paper 16685597 Paper 16528748 Paper 16432041 Paper 16364695 Paper 16060848 Paper 16027244 Paper 16007257 Paper 15957185 Paper 15821019 Paper 15814067 Paper 15746448 Paper 15699271 Paper 15683584 Paper 15596575 Paper 15591311 Paper 15358862 Paper 15313118 Paper 15302361 Paper 15231751 Paper 15229105 Paper 15220115 Paper 15140834 Paper 15140747 Paper 15138309 Paper 15121156 Paper 15107462 Paper 15047570 Paper 15016901 Paper 15001662 Paper 14732904 Paper 14678489 Paper 14585618 Paper 12972951 Paper 12925886 Paper 12909593 Paper 12871728 Paper 12740218 Paper 12670744 Paper 12659808 Paper 12646671 Paper 12646581 Paper 12563174 Paper 12523655 Paper 12496668 Paper 12464620 Paper 12438170 Paper 12378819 Paper 12225992 Paper 12067617 Paper 11992254 Paper 11896026

Abstract

In this Core, we will ask the question: "Does SNP stratification predict systemic therapeutic drug responses in large, prospective randomized, controlled USA clinical trials?" For this purpose, we have obtained access to two such clinical trials in hypertension and renal disease, wherein the therapeutic drug responses occur to a beta-adrenergic antagonist (metoprolol), an alpha-adrenergic antagonist (doxazosin), a calcium channel antagonist (amlodipine) ACE inhibitors (ramipril or lisinopril), or a diuretic (chlorthalidone).

View original record on NIH RePORTER →